Endsulin
Private Company
Funding information not available
Overview
Endsulin is a private, preclinical-stage biotech founded in 2018, headquartered in San Diego, CA (with a noted research base in Madison, WI), focused on a curative gene therapy for Type 1 Diabetes. The company's core platform involves delivering a genetic factor to hepatocytes to 'switch on' insulin production, aiming to restore the body's natural glucose regulation. Led by a founder with a transplant surgery background and advised by a seasoned Scientific Advisory Board, Endsulin is pursuing a potentially transformative, one-time treatment to free patients from the lifelong burden of insulin dependency.
Technology Platform
Liver-directed gene therapy using viral vectors to deliver a genetic factor that reprograms hepatocytes to become glucose-responsive insulin-producing cells, aiming for a one-time treatment without immunosuppression.
Opportunities
Risk Factors
Competitive Landscape
Endsulin competes in a crowded T1D curative space, including companies like Vertex Pharmaceuticals (stem cell-derived islet cell therapy, already in clinical trials), Sernova (cell pouch device), and ViaCyte (stem cell-derived cells). Other gene therapy approaches are also in early research. Endsulin's differentiation lies in its one-time, liver-targeted, potentially immunosuppression-free approach.